BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 11093363)

  • 1. An assessment of iloperidone for the treatment of schizophrenia.
    Jain KK
    Expert Opin Investig Drugs; 2000 Dec; 9(12):2935-43. PubMed ID: 11093363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iloperidone: a new benzisoxazole atypical antipsychotic drug. Is it novel enough to impact the crowded atypical antipsychotic market?
    Albers LJ; Musenga A; Raggi MA
    Expert Opin Investig Drugs; 2008 Jan; 17(1):61-75. PubMed ID: 18095919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New atypical antipsychotics for schizophrenia: iloperidone.
    Caccia S; Pasina L; Nobili A
    Drug Des Devel Ther; 2010 Feb; 4():33-48. PubMed ID: 20368905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iloperidone for the treatment of schizophrenia.
    Marino J; Caballero J
    Ann Pharmacother; 2010 May; 44(5):863-70. PubMed ID: 20388862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic.
    Citrome L
    Int J Clin Pract; 2009 Aug; 63(8):1237-48. PubMed ID: 19624791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Iloperidone: A new drug for the treatment of schizophrenia.
    Arif SA; Mitchell MM
    Am J Health Syst Pharm; 2011 Feb; 68(4):301-8. PubMed ID: 21289324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L; Meng X; Hochfeld M; Stahl SM
    Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iloperidone for schizophrenia.
    Rado J; Janicak PG
    Expert Opin Pharmacother; 2010 Aug; 11(12):2087-93. PubMed ID: 20586713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia.
    Kane JM; Lauriello J; Laska E; Di Marino M; Wolfgang CD
    J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S29-35. PubMed ID: 18334910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iloperidone: a new option for the treatment of schizophrenia.
    Cutler AJ
    Expert Rev Neurother; 2009 Dec; 9(12):1727-41. PubMed ID: 19951132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iloperidone for the treatment of schizophrenia.
    Bishop JR; Bishop DL
    Drugs Today (Barc); 2010 Aug; 46(8):567-79. PubMed ID: 20830317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacological profile of iloperidone, a novel atypical antipsychotic agent.
    Szewczak MR; Corbett R; Rush DK; Wilmot CA; Conway PG; Strupczewski JT; Cornfeldt M
    J Pharmacol Exp Ther; 1995 Sep; 274(3):1404-13. PubMed ID: 7562515
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended radioligand binding profile of iloperidone: a broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders.
    Kalkman HO; Subramanian N; Hoyer D
    Neuropsychopharmacology; 2001 Dec; 25(6):904-14. PubMed ID: 11750183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iloperidone for the management of adults with schizophrenia.
    Crabtree BL; Montgomery J
    Clin Ther; 2011 Mar; 33(3):330-45. PubMed ID: 21600386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies.
    Potkin SG; Litman RE; Torres R; Wolfgang CD
    J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S4-11. PubMed ID: 18334911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ACS chemical neuroscience molecule spotlight on Fanapt.
    Hopkins CR
    ACS Chem Neurosci; 2010 Jun; 1(6):410. PubMed ID: 22778835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia.
    Cutler AJ; Kalali AH; Weiden PJ; Hamilton J; Wolfgang CD
    J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S20-8. PubMed ID: 18334909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials.
    Weiden PJ; Cutler AJ; Polymeropoulos MH; Wolfgang CD
    J Clin Psychopharmacol; 2008 Apr; 28(2 Suppl 1):S12-9. PubMed ID: 18334908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion.
    Citrome L
    Expert Opin Drug Metab Toxicol; 2010 Dec; 6(12):1551-64. PubMed ID: 21034370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults.
    Bobo WV
    Expert Rev Clin Pharmacol; 2013 Jan; 6(1):61-91. PubMed ID: 23272794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.